DetermaRx™ is a molecular stratification test to identify patients with IA-IIA non-squamous non-small cell lung cancer (NSCLC) who may be at low- or high-risk of having a recurrence.1
patients are diagnosed with early-stage non-small cell lung cancer (NSCLC) each year.2
Despite complete surgical resection,
up to 45%
of early-stage patients will not survive past five years.3
DetermaRx provides a
to understand which patients may benefit from adjuvant therapy.
Now paired from the same tissue sample, DetermaRx + EGFR™ is the complete molecular testing solution in early-stage NSCLC, guiding treatment selection and sequencing of targeted therapy (osimertinib) and adjuvant chemotherapy.
Here’s How DetermaRx Works
Identify your patients who may benefit from adjuvant treatment
Order DetermaRx for your patients with stage IA-IIA non-squamous NSCLC undergoing resection. You may also opt in for EGFR mutation analysis on the same tissue sample if you wish.
We analyze the molecular signature of your patient’s tumor tissue to stratify your patient’s risk for recurrence.
- DetermaRx is a 14-gene molecular stratification test that has been validated in two independent cohorts with close to 1400 patients.4
- DetermaRx outperformed NCCN criteria in identifying patients at high risk for mortality from stage IA, IB, and IIA non-squamous NSCLC.4
- Test-identified high-risk* patients who were treated adjuvant platinum doublet chemotherapy had 97.0% 5-year freedom from recurrence (FFR) compared to 72.4% 5-year FFR for high-risk patients who did not receive chemotherapy.1
- Significant difference in survival amongst chemotherapy treated vs. untreated high-risk* patients was reinforced in an expanded 250 patient prospective cohort, in which majority of patients were stage IA.1
- DetermaRx identified high-risk patients who responded to adjuvant chemotherapy, independent of EGFR status.1
*Test identified intermediate- and high-risk patients were grouped together in this analysis and designated as molecular high-risk.
“The integration of testing for targeted therapy, including EGFR mutation status and chemotherapy selection by DetermaRx on the same sample, will enable oncologists to optimize and sequence treatment post-surgery. In my opinion, these two tests together close the few remaining gaps that we currently face in deciding adjuvant therapy for early-stage adenocarcinoma of the lung. With these results, I would feel confident initiating chemotherapy, followed by targeted therapy for the EGFR-positive, DetermaRx high-risk patients I see in my practice.”
We are committed to providing accessible, affordable testing for all
Insurance and Eligibility
We accept all insurance on an out-of-network basis. We will contact you if your estimated out-of-pocket cost exceeds $100.
1. Woodard GA, et al. (2021) Molecular risk stratification is independent of EGFR mutation status in identifying early-stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy. Clin Lung Cancer 22:587-595.
2. SEER data.
3. Chansky, et al. (2017) The IASLC Lung Cancer Staging Project: External validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 12:1109
4. Kratz, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies. Lancet 379:823.